ASND241220C230000
- 0.05
- 0.000.00%
Ascendis Pharma A/S Newsroom
Ascendis Pharma (ASND) Gets a Buy From Stifel Nicolaus
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207
Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald
Oppenheimer Adjusts Ascendis Pharma A/S Price Target to $180 From $190, Maintains Outperform Rating
Ascendis Pharma Is Maintained at Buy by Stifel
Ascendis Pharma Analyst Ratings
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $153
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $289
Ascendis Pharma Analyst Ratings
Ascendis Pharma (ASND) Receives a Buy From Cantor Fitzgerald
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167